Restriction-mediated differential display (RMDD) identifies pip92 as a pro-apoptotic gene product induced during focal cerebral ischemia.
Studies of gene expression changes after cerebral ischemia can provide novel insight into ischemic pathophysiology. Here we describe application of restriction-mediated differential display to screening for differentially expressed genes after focal cerebral ischemia. This method combines the nonredundant generation of biotin-labeled fragment sets with the excellent resolution of direct blotting electrophoresis, reliable fragment recovery, and a novel clone selection strategy. Using the filament model in mouse with 90 minutes MCA occlusion followed by 2, 6, and 20 hours reperfusion, we have compared gene expression in sham-operated animals to both the ipsi- and contralateral forebrain hemisphere of ischemic mice. Our screening method has resulted in the identification of 70 genes differentially regulated after transient middle cerebral artery occlusion (MCAO), several of which represent unknown clones. We have identified many of the previously published regulated genes, lending high credibility to our method. Surprisingly, we detected a high degree of correspondent regulation of genes in the nonischemic hemisphere. A high percentage of genes coding for proteins in the respiratory chain was found to be up-regulated after ischemia, potentially representing a new mechanism involved in counteracting energy failure or radical generation in cerebral ischemia. One particularly interesting gene, whose upregulation by ischemia has not been described before, is pip92; this gene shows a rapid and long-lasting induction after cerebral ischemia. Here we demonstrate that pip92 induces cell death in primary neurons and displays several hallmarks of pro-apoptotic activity upon overexpression, supporting the notion that we have identified a novel pathophysiological player in cerebral ischemia. In summary, restriction-mediated differential display has proven its suitability for screening complex samples such as brain to reliably identify regulated genes, which can uncover novel pathophysiological mechanisms.
Schneider
Armin
A
Department of Molecular Neurology, Axaron Bioscience AG, Im Neuenheimer Feld 515, 69120 Heidelberg, Germany. schneider@axaron.de
Fischer
Achim
A
Weber
Daniela
D
von Ahsen
Oliver
O
Scheek
Sigrid
S
Krüger
Carola
C
Rossner
Moritz
M
Klaussner
Bettina
B
Faucheron
Nadine
N
Kammandel
Birgitta
B
Goetz
Bernhard
B
Herrmann
Oliver
O
Bach
Alfred
A
Schwaninger
Markus
M
D000818:Animals; D017209:Apoptosis; D002545:Brain Ischemia / Q000503:physiopathology*; D019556:COS Cells; D053938:DNA Fragmentation; D020869:Gene Expression Profiling / Q000379:methods*; D005786:Gene Expression Regulation; D017874:Immediate-Early Proteins; D020244:Infarction, Middle Cerebral Artery; D051379:Mice; D009474:Neurons / Q000166:cytology / Q000502:physiology; D020411:Oligonucleotide Array Sequence Analysis; D011506:Proteins / Q000235:genetics / Q000378:metabolism*; D013997:Time Factors
D017874:Immediate-Early Proteins; D011506:Proteins; C066505:Ier2 protein, mouse